

Oreste Segatto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8407326/publications.pdf>

Version: 2024-02-01

37
papers

2,726
citations

318942

23
h-index

388640

36
g-index

39
all docs

39
docs citations

39
times ranked

2866
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma. Trends in Cancer, 2022, 8, 83-86. | 3.8 | 6 |
| 2 | FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. Journal of Hepatology, 2021, 75, 351-362. | 1.8 | 35 |
| 3 | Making sense of Cbp/p300 loss of function mutations in skin tumorigenesis. Journal of Pathology, 2020, 250, 3-6. | 2.1 | 5 |
| 4 | Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer, 2020, 123, 1047-1059. | 2.9 | 37 |
| 5 | HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma. Hepatology, 2019, 69, 131-142. | 3.6 | 27 |
| 6 | Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver International, 2019, 39, 43-62. | 1.9 | 54 |
| 7 | miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling. EMBO Molecular Medicine, 2018, 10, . | 3.3 | 23 |
| 8 | Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator. Cell, 2016, 165, 1031-1034. | 13.5 | 1 |
| 9 | Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics. Seminars in Cell and Developmental Biology, 2016, 50, 115-124. | 2.3 | 20 |
| 10 | Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation. PLoS ONE, 2015, 10, e0129859. | 1.1 | 8 |
| 11 | Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget, 2015, 6, 35183-35201. | 0.8 | 75 |
| 12 | A pervasive role for MIG6 in restraining cell proliferation. Cell Death and Differentiation, 2014, 21, 345-347. | 5.0 | 5 |
| 13 | Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic. Journal of Molecular Medicine, 2014, 92, 681-695. | 1.7 | 15 |
| 14 | Regulation of Epidermal Growth Factor Receptor Signaling by Endocytosis in Normal and Malignant Cells. , 2013, , 279-302. | | 1 |
| 15 | Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. Journal of Cell Science, 2011, 124, 1785-1793. | 1.2 | 87 |
| 16 | Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6912-6917. | 3.3 | 109 |
| 17 | A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. Journal of Cell Biology, 2010, 189, 557-571. | 2.3 | 102 |
| 18 | The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity. Oncogene, 2007, 26, 7833-7846. | 2.6 | 67 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Targeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Wavedá€like phenotype. <i>EMBO Reports</i> , 2005, 6, 755-761. | 2.0 | 44 |
| 20 | Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. <i>Oncogene</i> , 2005, 24, 4540-4548. | 2.6 | 111 |
| 21 | Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. <i>Experimental Cell Research</i> , 2005, 305, 343-354. | 1.2 | 73 |
| 22 | Feedback inhibition by RALT controls signal output by the ErbB network. <i>Oncogene</i> , 2003, 22, 4221-4234. | 2.6 | 112 |
| 23 | Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. <i>Oncogene</i> , 2002, 21, 6530-6539. | 2.6 | 73 |
| 24 | Negative regulation of receptor tyrosine kinase signals. <i>FEBS Letters</i> , 2001, 490, 132-141. | 1.3 | 32 |
| 25 | Inhibition of ErbB-2 Mitogenic and Transforming Activity by RALT, a Mitogen-Induced Signal Transducer Which Binds to the ErbB-2 Kinase Domain. <i>Molecular and Cellular Biology</i> , 2000, 20, 7735-7750. | 1.1 | 134 |
| 26 | Expression of gp 185HER-2 in human cutaneous melanoma: Implications for experimental immunotherapeutics. <i>International Journal of Cancer</i> , 1994, 56, 341-346. | 2.3 | 32 |
| 27 | Production and Characterization of Murine mAbs to the Extracellular Domain of Human Neu Oncogene Product GP185HER2. <i>Hybridoma</i> , 1992, 11, 519-527. | 0.9 | 31 |
| 28 | Changes in expression of $\alpha 4 \beta 1$ integrin heterodimer in primary and metastatic breast cancer. <i>British Journal of Cancer</i> , 1992, 66, 318-322. | 2.9 | 113 |
| 29 | Cloning, expression, and biological effects of gene in mammalian cells. <i>Methods in Enzymology</i> , 1991, 198, 272-277. | 0.4 | 6 |
| 30 | EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. <i>Science</i> , 1990, 248, 79-83. | 6.0 | 140 |
| 31 | The human transforming growth factor type alpha coding sequence is not a direct-acting oncogene when overexpressed in NIH 3T3 cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987, 84, 3733-3737. | 3.3 | 63 |
| 32 | erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. <i>Science</i> , 1987, 237, 178-182. | 6.0 | 972 |
| 33 | Multiple epitope recognition: An approach to improved radioimmuno-detection of tumor-associated antigens. <i>International Journal of Cancer</i> , 1987, 39, 729-736. | 2.3 | 19 |
| 34 | Clinical improvement and partial correction of the T cell defects of acquired immunodeficiency syndrome (AIDS) and lymphadenopathy syndrome (LAS) by a calf thymus acid lysate. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 531-532. | 0.9 | 4 |
| 35 | Lymphoid stroma of Warthin's tumor: Phenotypic analogies with gut-associated lymphoid tissue. <i>Clinical Immunology and Immunopathology</i> , 1985, 34, 39-47. | 2.1 | 9 |
| 36 | Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens. <i>Immunogenetics</i> , 1984, 19, 109-116. | 1.2 | 77 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Isolation of viable melanoma cells from surgically removed lesions using dishes coated with monoclonal antibody to a high molecular weight melanoma associated antigen. Journal of Immunological Methods, 1983, 62, 337-346. | 0.6 | 3 |